HomeDragonfruitTablegrapesAustraliaGreeceBangladeshStrawberry
New Listings    Hot Listings    Top Rated    Editor Pick    Add a Listing     Upgrade a Listing    Update a Listing    Get Rated    Suggest a Category    Contact
+ Main Category

Crops: 672
Biology: 398
Research: 2032
Business: 39
Home Gardening: 73

+ Tell a Friend

Fill out the information below to email a friend a brief note about 'Pomology: Fruit Cultivation and Production'

Your Name:
    
Your Email:
    
Friend's Name:
    
Friend's Email:
    

    


+ Top 10

TropHort: Biology, Agriculture, Horticulture and Forestry
Olericulture: Vegetable Cultivation and Production
Pomelo - Wikipedia, the free encyclopedia
Apple - Wikipedia, the free encyclopedia
Viticulture - Wikipedia, the free encyclopedia
Information Sheet - Apple Facts
Grape and wine industry.
Texas Winegrape Network - A Viticulture Resource for Grape Growers.
Life and Earth Sciences Social Network
Table Grape Cultivars for Illinois.

   

+ Directory Statistics


Links: 1182
Categories: 54
Registered Users: 178
Mailing List Subscribers: 24

+ Pagerank Statistics

PR 7
3 site(s)
PR 6
42 site(s)
PR 5
88 site(s)
PR 4
184 site(s)
PR 3
207 site(s)
PR 2
95 site(s)
PR 1
32 site(s)

+ Join Mailing List

Joining mailing list will entitle you to receive occasional emails informing you of news and updates to the site and any special offers that may be of interest to you.


Research > Chapter 11005



Bookmarks

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array

Loss heterozygosity decreased expression NME genes correlate teratomatous differentiation human male germ cell tumors.

Loss heterozygosity genomic instability synchronous endometrioid tumors ovary endometrium.

Loss heterozygosity heterogeneity appearance persisting acute myeloid leukemia myelodysplastic syndromes.

Loss heterozygosity histone hypoacetylation PINX1 gene reduced expression gastric carcinoma.

Loss heterozygosity homozygous deletions 9p21-22 melanoma.

Loss heterozygosity human telomerase reverse transcriptase (hTERT) expression bronchial mucosa heavy smokers.

Loss heterozygosity correlation medical outcome Epstein-Barr virus infection nasopharyngeal carcinoma.

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

Loss heterozygosity lack mutations XPG/ERCC5 DNA repair gene 13q33 prostate cancer.

Loss heterozygosity linkage examination breast carcinoma - Indication putative vulnerability gene short arm chromosome 8.

Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer

Loss of heterozygosity and methylation of p16 in renal cell carcinoma

Loss heterozygosity microsatellite alterations p53 RB genes adenoid cystic carcinoma salivary glands.

Loss heterozygosity microsatellite instability RAD52 RAD54 loci breast cancer.

Loss heterozygosity microsatellite instability chromosomal sites 1q 10q morphologically distinct regions late stage prostate lesions.

Loss of heterozygosity and microsatellite instability at the MLL locus are common in childhood acute leukemia, but not in infant acute leukemia

Loss of heterozygosity and microsatellite instability in De Novo versus ex-adenoma carcinomas of the colorectum

Loss heterozygosity microsatellite instability breast hyperplasia - No obligate correlation genetic alterations succeeding malignancy.

Loss heterozygosity microsatellite instability chromosome 6q25 area laryngeal carcinoma.

Loss heterozygosity microsatellite instability ductal carcinoma situ breast.

Loss heterozygosity microsatellite instability hepatocellular carcinoma Taiwan.

Loss heterozygosity microsatellite instability human atherosclerotic plaques.

Loss heterozygosity microsatellite instability human non-neoplastic hepatic lesions.

Loss heterozygosity microsatellite instability larynx cancer.

Loss heterozygosity microsatellite instability male breast cancer.

Loss heterozygosity microsatellite instability tumor-associated stromal cells tumor epithelium prostate cancer.

Loss heterozygosity microsatellite instability H-ras gene cancer head neck.

Loss heterozygosity microsatellite instability chromosome arm 10q neuroblastoma.

Loss of heterozygosity and mitotic linkage maps in the mouse

Loss heterozygosity mutational alterations p53 gene skin tumours interspecific hybrid mice.

Loss heterozygosity mutational analyses ACTRII gene locus human colorectal tumors.

Loss heterozygosity nonsense mutation Apc azoxymethane-induced colonic tumours Min mice.

Loss heterozygosity overexpression p53 gene ovarian carcinoma.

Loss heterozygosity p53 expression pterygium.

Loss heterozygosity p53 gene mutations breast cancer.

Loss heterozygosity p53 polymorphism Pro72Arg young patient medulloblastoma.

Loss heterozygosity point mutation Aprt locus T cells fibroblasts Pms2-/- mice.

Loss heterozygosity promoter methylation, mutation, underlie loss TFF1 gastric carcinoma.

Loss of heterozygosity and protein expression of APC gene in renal cell carcinomas

Loss heterozygosity reduced expression CUTL1 gene uterine leiomyomas.

Loss of heterozygosity and somatic mutations of the Glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course

Loss heterozygosity somatic mutations VHL tumor suppressor gene sporadic cerebellar hemangioblastomas.

Loss of heterozygosity and the origin of meningioma

Loss heterozygosity smoking index increase decrease differentiation lung adenocarcinomas - Etiologic implications.

Loss heterozygosity transcriptome analyses 1.2 Mb candidate ovarian cancer tumor suppressor locus area 17q25.1-q25.2.

Loss heterozygosity tumor suppressor activity Bin1 prostate carcinoma.

Loss heterozygosity tumor suppressor gene mutations chondrosarcomas.

Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis

Loss of heterozygosity associated with uniparental disomy in breast carcinoma

Loss heterozygosity 10q tumors upper respiratory tract poor prognosis.

Loss heterozygosity 11p13 Wilms tumours necessarily involve mutations WT1 gene.

Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas

Loss heterozygosity 11p15 malignant glioma.

Loss of heterozygosity at 11q13: Analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1

Loss heterozygosity 11q22-q23 breast cancer.

Loss heterozygosity 11q23.1 survival breast cancer - Results big European study.

Loss heterozygosity 11q23.1 breast carcinomas - Indication involvement gene distal close ATM.

Loss heterozygosity 11q23.3 vasculoinvasive metastatic squamous cell carcinoma cervix.

Loss heterozygosity 12P12-13 primary metastatic prostate adenocarcinoma.

Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression

Loss heterozygosity 12q14-15 occurs Stage I soft tissue sarcomas MDM2 amplification tumors stages.

Loss heterozygosity 13q14 13q21 high grade, high stage prostate cancer.

Loss heterozygosity 13q14 correlates RB1 gene underexpression human breast cancer.

Loss heterozygosity 15q21.3 correlates incidence metastases head neck cancer.

Loss heterozygosity 16q24.1-q24.2 significantly metastatic aggressive behavior prostate cancer.

Loss heterozygosity 17p13.3-ter, distal TP53, correlates negative hormonal phenotype sporadic breast cancer.

Loss heterozygosity 18q21 indicative recurrence poor prognosis subset colorectal cancers.

Loss heterozygosity 18q21 area gastric cancer involves number cancer-related genes correlates stage histology, lacks independent prognostic.

Loss heterozygosity 1p, 8p, 10p, 13q, 17p advanced urothelial cancer lack relationship chemotherapy answer outcome.

Loss heterozygosity 1p36 independently predicts disease progression decreased survival probability neuroblastoma patients. Children's Cancer Group study.

Loss heterozygosity 1p36 predicts poor prognosis gastrointestinal stromal/smooth muscle tumors.

Loss heterozygosity 3p benign lesions preceding invasive breast cancer.

Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus

Loss heterozygosity 3p23 correlated poor survival patients colorectal carcinoma.

Loss heterozygosity 3p24-p25 prognostic factor breast cancer.

Loss heterozygosity 4p16.3 mutation FGFR3 transitional cell carcinoma.

Loss heterozygosity 5q21 non-small cell lung cancer. frequent event proof APC mutation.

Loss heterozygosity 5q21-22 (adenomatous polyposis coli gene) oral squamous cell carcinoma usual correlated advanced disease.

Loss heterozygosity 6q frequent concurrent 3p loss sporadic familial capillary hemangioblastomas.

Loss heterozygosity 7p Wilms tumour progress.

Loss heterozygosity 7q22 mutation examination CDP gene human epithelial ovarian tumors.

Loss heterozygosity 7q31 breast cancer - Results International Collaborative Investigation Group.

Loss heterozygosity 7q31.1 12p13-12 advanced prostate cancer.

Loss heterozygosity 9P 17q human laryngeal tumours.

Loss heterozygosity 9p21 loci mutations MTS1 MTS2 genes human lung cancers.

Loss heterozygosity 9p23 defines locus non-small cell lung cancer.

Loss heterozygosity 9q33 hypermethylation DBCCR1 gene oral squamous cell carcinoma.

Loss of heterozygosity at APC and MCC genes of oral cancer and leukoplakia tissues from Indian tobacco chewers

Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation

Loss heterozygosity D14S62 D14S51 detected simple non-radioactive technique plasma DNA potential marker metastasis recurrence curative hepatic resection hepatocellular carcinoma.

Loss of heterozygosity at D14S62 and metastatic potential of breast cancer

Loss heterozygosity cellular senescence locus human chromosome 2 types tumors.

Loss heterozygosity autosomal linked loci tumor progression patient melanoma.

Loss heterozygosity chromosomal regions 3p 13q cell carcinoma lung represents frequency events.

Loss heterozygosity chromosome 11 breast cancer - Association prognostic factors genetic alterations.

Loss heterozygosity chromosome 11p15 Wilms tumors - Identification independent regions.

Loss heterozygosity chromosome 11q lung adenocarcinoma - Identification independent regions.

Loss heterozygosity chromosome 13q hepatocellular carcinoma - Identification independent regions.

Loss heterozygosity chromosome 16q prostate adenocarcinoma - Identification independent regions.

Loss heterozygosity chromosome 17p HER-2 amplification lack nodal involvement breast cancer.

Loss heterozygosity chromosome 1p diverse solid human tumours - Association survival.

Loss heterozygosity chromosome 1p human breast cancer - Association high S-phase, reduced patient survival deletions chromosome regions.

Loss heterozygosity chromosome 1q22 basal cell carcinomas exclusion basal cell nevus syndrome gene site.

Loss heterozygosity chromosome 3P14-24 patients breast cancer.

Loss heterozygosity chromosome 3p correlates telomerase activity renal cell carcinoma.

Loss heterozygosity chromosome 3p microdissected non-small cell lung cancer.

Loss of heterozygosity at chromosome 6 as a marker of early genetic alterations in cervical intraepithelial neoplasias and microinvasive carcinomas

Loss heterozygosity chromosome 6q correlates tumor progression patient survival.

Loss heterozygosity chromosome 6q preinvasive early invasive breast carcinomas.

Loss of heterozygosity at chromosome 6q23-25 correlates with clinical and histologic parameters in salivary gland adenoid cystic carcinoma

Loss heterozygosity chromosome 7q human breast cancer - Association medical variables.

Loss heterozygosity chromosome 8p21-p23 adenocarcinoma gastric cardia.

Loss heterozygosity chromosome 9p ductal carcinoma situ invasive carcinoma breast.

Loss heterozygosity chromosome 9p21 (INK4-p14ARF locus) - Homozygous deletions mutations p16 p14ARF genes sporadic primary melanomas.

Loss heterozygosity chromosome 9p21 primary neuroblastomas - Proof deleted regions.

Loss heterozygosity chromosome 9p21 frequent result enteropathy-type T-cell lymphoma.

Loss heterozygosity chromosome 9q22-31 frequent early event ovarian tumors.

Loss heterozygosity chromosome arm 13q RB1 status human prostate cancer.

Loss heterozygosity chromosome regions 22q11-12 11p15.5 renal Rhabdoid tumors.

Loss heterozygosity chromosome segment Xq25-26.I advanced human ovarian carcinomas.

Loss heterozygosity chromosome segments 8p22 8p11.2-21.1 transitional-cell carcinoma urinary bladder.

Loss heterozygosity chromosomes 3, 6, 8, 11, 16, 17 ovarian cancer - Correlation clinicopathological variables.

Loss heterozygosity chromosomes 3p 17p primary non-small cell lung cancer.

Loss heterozygosity chromosomes 8p, 9p, 14q stage grade non-papillary renal cell carcinomas.

Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours

Loss heterozygosity d3s2 locus short arm chromosome 3 chronic myelogenous leukemia.

Loss heterozygosity loci chromosome arm 22Q human sporadic breast carcinomas.

Loss heterozygosity loci candidate tumor suppressor genes microdissected primary non-small cell lung cancer.

Loss heterozygosity loci chromosome 4 usual genetic event spontaneous immortalization mouse embryonic fibroblasts.

Loss heterozygosity locus F13B chromosome 1q human medulloblastoma.

Loss heterozygosity microsatellite markers area p11-21 chromosome 8 microdissected breast tumor peritumoral cells.

Loss heterozygosity pseudoautosomal regions human breast cancer association negative hormonal phenotype.

Loss heterozygosity selective sites chromosomes 13 17 human breast carcinoma.

Loss heterozygosity 5,10-methylenetetrahydrofolate reductase locus human ovarian carcinomas.

Loss heterozygosity ATM locus colorectal carcinoma.

Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls

Loss heterozygosity BRCA1 locus Tunisian women sporadic breast cancer.

Loss heterozygosity DCC gene locus crucial acquisition metastatic potential oesophageal squamous cell carcinoma.

Loss heterozygosity FHIT gene diverse solid human tumours association survival colorectal cancer patients.

Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells

Loss heterozygosity N-ras locus 7,12-dimethylbenz(a)anthracene-induced rat leukemia.

Loss heterozygosity NAD(P)H:Quinone oxidoreductase locus increased resistance mitomycin C human bladder carcinoma cell line.

Loss heterozygosity RB locus correlates loss RB protein primary malignant neuro-endocrine lung carcinomas.

Loss heterozygosity RB-1 locus pRB immunostaining epithelial ovarian tumors. molecular, immunohistochemical, clinicopathologic study.

Loss heterozygosity RET protooncogene locus case multiple endocrine neoplasia type 2A.

Loss heterozygosity SS receptor type 5 locus human GH- TSH-secreting pituitary adenomas.

Loss heterozygosity TP53 gene - Independent incidence genetic instability events node-negative breast cancer.

Loss heterozygosity alpha-inhibin locus chromosome 2q attribute human granulosa cell tumors.

Loss heterozygosity bcl-2 gene locus expression bcl-2 human gastric colorectal carcinomas.

Loss heterozygosity raf locus cell lung carcinoma.

Loss heterozygosity dilute-short ear (Myo5a-Bmp5) area mouse - Mitotic recombination double non-disjunction?

Loss heterozygosity dilute-short ear (Myo5a-Bmp5) area mouse - mitotic recombination double non-disjunction?

Loss heterozygosity familial RCC (3;8) locus clear cell renal carcinomas.

Loss heterozygosity human rap1a krev 1 locus rare event colorectal tumors.

Loss heterozygosity mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients radiation-induced lung injury.

Loss heterozygosity mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates poor differentiation early breast carcinomas.

Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: A frequent but late event in adrenocortical tumorigenesis

Loss heterozygosity p53, RB, DCC, APC tumor suppressor gene loci human bladder cancer.

Loss heterozygosity proximal-mid part mouse chromosome 4 defines tumor suppressor gene loci T-cell lymphomas.

Loss heterozygosity rb locus frequent correlates muscle invasion bladder carcinoma.

Loss heterozygosity retinoblastoma locus human pituitary tumors.

Loss heterozygosity short arm chromosome 3 microdissected cervical intraepithelial neoplasia.

Loss heterozygosity short arm chromosome 3 renal-cell cancer correlates cytological tumour type.

Loss heterozygosity mitotic recombination diploid strain Aspergillus nidulans answer castor oil plant detergent.

Loss heterozygosity detected short tandem repeat (STR) locus commonly human DNA diagnosis.

Loss heterozygosity progress progression differentiated adenocarcinoma stomach.

Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene

Loss heterozygosity 10q loci human gliomas.

Loss heterozygosity DNA polymorphisms mapping chromosomes 10 17 prognosis patients gliomas.

Loss heterozygosity chromosome 3 sequencing 3p21 cell lung cancer.

Loss heterozygosity alleles chromosome 10 human brain tumours.

Loss heterozygosity alleles chromosome 11 cervical carcinoma.

Loss heterozygosity chromosome 11 Epstein-Barr-Virus nasopharyngeal carcinoma.

Loss heterozygosity chromosome 11 adenocarcinoma stomach.

Loss heterozygosity chromosome 14q neuroblastoma.

Loss heterozygosity chromosome area 11p15 wilms tumors similar hras gene transforming mutations.

Loss heterozygosity chromosomes 1 14 defines subsets advanced neuroblastomas.

Loss heterozygosity chromosomes 16q 1p Wilms tumors predicts adverse outcome.

Loss heterozygosity defined regions chromosomes 3, 11 17 carcinomas uterine cervix.

Loss heterozygosity distal markers 22q human gliomas.

Loss heterozygosity genes 11p medical patients lung carcinoma.

Loss heterozygosity loci chromosome 10 morphologically malignant meningioma progression.

Loss heterozygosity loci chromosome 17p human malignant astrocytoma.

Loss heterozygosity loci long arm chromosome 6 human malignant melanoma.

Loss heterozygosity NF2 gene retinal optic nerve lesions patients neurofibromatosis 2.

Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas correlation with n myc amplification

Loss heterozygosity short arm chromosome 11 (11p15) human milk epithelial cells immortalized microinjection SV40 DNA.

Loss heterozygosity short arm chromosome 11 11p15 human milk epithelial cells immortalized microinjection sv 40 dna.

Loss heterozygosity short arm chromosome 7 sporadic Wilms tumour.

Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen- and tissue-dependent

Loss heterozygosity frequently affects chromosome 17q non-small cell lung cancer.

Loss heterozygosity short arm chromosome 8 early event breast cancers.

Loss heterozygosity short arm chromosome 8 invasive behavior breast cancer.

Loss heterozygosity identifies genetic chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes chronic myelomonocytic leukemia.

Loss heterozygosity identifies multiple sites allelic deletions chromosome 1 human male germ cell tumors.

Loss heterozygosity (LewisXF344)F1 rat urinary bladder tumors stimulated N-butyl-N-(4-hydroxybutyl)nitrosamine dimethylarsinic acid sodium L-ascorbate.

Loss heterozygosity 11q13-14 regions gastric neuroendocrine tumors multiple endocrine neoplasia type 1 syndrome.

Loss heterozygosity 3 embryonal tumors recommends usual pathogenetic mechanism.

Loss heterozygosity 8p microinvasion colorectal carcinoma.

Loss heterozygosity 9pterapprxp21 primary esophageal squamous cell carcinomas.

Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer

Loss heterozygosity DNA mismatch repair genes human atherosclerotic plaques.

Loss heterozygosity Pseudoexfoliation syndrome.

Loss heterozygosity gene coding thyroid hormone receptor lung cancers.

Loss heterozygosity actinic keratosis, squamous cell carcinoma sun-exposed normal-appearing skin Japanese - Difference Japanese Caucasians.

Loss heterozygosity acute leukemia - proof frequent submicroscopic deletions.

Loss heterozygosity adenomyosis hMSH2, hMLH1, p16Ink4 GALT loci.

Loss heterozygosity ampulla Vater neoplasms adenoma-carcinoma sequence.

Loss heterozygosity asbestos-induced mutations human mesothelioma cell line.

Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk

Loss of heterozygosity in bilateral breast cancer

Loss of heterozygosity in cervical carcinoma: Subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24

Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24

Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis

Loss of heterozygosity in childhood de novo acute myelogenous leukemia

Loss heterozygosity chondrosarcomas markers linked hereditary multiple exostoses loci chromosomes 8 11.

Loss heterozygosity chromosomal area 16q24.3 progression prostate cancer.

Loss heterozygosity chromosome 4q12-q13 hepatocellular carcinoma inern African blacks.

Loss heterozygosity chromosome Xp22.2-p22.13 Xq26.1-q27.1 human breast carcinomas.

Loss heterozygosity chromosomes 1, 5, 7 13 mouse hepatoma detected systematic genome-wide scanning RLGS genetic map.

Loss heterozygosity chromosomes 1,5,7 13 mouse hepatoma detected systematic genome-wide scanning RLGS genetic map.

Loss heterozygosity medical stage IB cervical carcinoma - Relationships medical histopathologic features.

Loss heterozygosity clonal evolution genetic progression divergence spindle cell carcinoma gallbladder.

Loss heterozygosity ductal carcinoma situ breast.

Loss heterozygosity ductal lavage breast tumor contralateral breast.

Loss heterozygosity dysplasia carcinoma gallbladder.

Loss heterozygosity endometrial carcinoma.

Loss heterozygosity familial breast carcinomas.

Loss heterozygosity familial tumors BRCA1-linked kindreds.

Loss of heterozygosity in fibrocystic change of the breast: Genetic relationship between benign proliferative lesions and associated carcinomas

Loss heterozygosity follicular papillary thyroid carcinomas.

Loss heterozygosity gastric neuroendocrine tumor.

Loss heterozygosity human aberrant crypt foci (ACF) putative precursor colon cancer.

Loss heterozygosity human breast carcinomas ataxia telangiectasia Cowden disease BRCA1 gene regions.

Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13

Loss heterozygosity human germinal tumors.

Loss heterozygosity human ovarian cancer chromosome 19q.

Loss heterozygosity human primary prostate carcinomas. potential tumor suppressor gene 7q31.1.

Loss heterozygosity human skin.

Loss of heterozygosity in hypotriploid cell cultures from testicular tumors

Loss heterozygosity invasive situ cervical carcinomas China.

Loss of heterozygosity in lobular carcinoma in situ of the breast

Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10

Loss heterozygosity malignant melanoma loci chromosomes 11 17 implicated pathogenesis cancers.

Loss of heterozygosity in malignant rat schwannomas chemically induced in hybrids of inbred rat strains with differential tumor susceptibility

Loss heterozygosity mammalian cell mutagenesis molecular examination spontaneous mutations aprt locus cho cells.

Loss heterozygosity normal breast epithelial tissue benign breast lesions BRCA1/2 carriers breast cancer.

Loss heterozygosity normal tissue adjacent breast carcinomas.

Loss heterozygosity p53, BRCA1, estrogen receptor genes correlation expression p53 protein ovarian epithelial tumors diverse cell types biological behavior.

Loss heterozygosity papillary follicular thyroid carcinoma. mini review.

Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor

Loss heterozygosity patients pseudoexfoliation syndrome.

Loss of heterozygosity in polycystic kidney disease with a missense mutation in the repeated region of PKD1

Loss heterozygosity renal hepatic epithelial cystic cells ADPKD1 patients.

Loss heterozygosity renal cell carcinoma.

Loss heterozygosity serial plasma DNA samples follow-up women breast cancer.

Loss heterozygosity somatic cells mouse. An important step cancer initiation?

Loss heterozygosity spontaneous X-ray-induced intestinal tumors arising F1 hybrid Min mice - Proof sequential loss Apc+ Dpc4 tumor progress.

Loss heterozygosity spontaneous chemically stimulated tumors B6C3F1 mouse.

Loss heterozygosity sporadic breast tumours BRCA2 locus chromosome 13q12-q13.

Loss heterozygosity sporadic human breast carcinoma. usual area 11q22 11q23.3.

Loss heterozygosity sporadic parathyroid tumours - Involvement chromosome 1 MEN1 gene locus 11q13.

Loss heterozygosity sporadic primary cutaneous melanoma.

Loss heterozygosity squamous cell carcinomas head neck defines tumor suppressor gene area 11q13.

Loss heterozygosity HLA class I area human pancreatic cancer.

Loss heterozygosity Hodgkin-Reed Sternberg cell line L1236.

Loss heterozygosity MXI1 gene frequent incidence melanoma.

Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer

Loss heterozygosity RAD54B area predictive breast carcinomas.

Loss heterozygosity VNTR area intron 1 P53 retinoblastoma cases.

Loss of heterozygosity in the chromosomal region 12p12-13 is very common in childhood acute lymphoblastic leukemia and permits the precise localization of a tumor-suppressor gene distinct from p7-KIP1

Loss heterozygosity clonal evolution flat colorectal neoplasms.

Loss heterozygosity area including BRCA1 gene 17q colon cancer.

Loss heterozygosity area chromosome 4p15.1-4q12 nasopharyngeal carcinoma patients familial history.

Loss heterozygosity retinoblastoma tumor suppressor gene skull base chordomas chondrosarcomas.

Loss heterozygosity tuberous sclerosis (TSC2) area chromosome band 16p13 occurs sporadic TSC-associated renal angiomyolipomas.

Loss heterozygosity tuberous sclerosis gene regions adenocarcinoma lung accompanied multiple atypical adenomatous hyperplasia.

Loss heterozygosity tuberous sclerosis hamartomas.

Loss heterozygosity tumor cells recurrent mandibular giant cell granuloma neurofibromatosis type 1.

Loss heterozygosity tumor cells requires re-evaluation - The data biased size-dependent differential sensitivity allele detection.

Loss heterozygosity tumour-adjacent normal tissue breast bladder cancer.

Loss heterozygosity common variant carcinomas endometrium.

Loss heterozygosity wilms tumor involves distinct regions chromosome 11.

Loss heterozygosity wilms tumors studied putative tumor suppressor regions limited chromosome 11.

Loss heterozygosity yeast occur ultraviolet irradiation S phase cell cycle.

Loss of heterozygosity induced by a chromosomal double-strand break

Loss heterozygosity involves multiple tumor suppressor genes human esophageal cancers.

Loss heterozygosity involving DCC gene human colorectal cancers correlated metastatic potential.

Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers

Loss heterozygosity involving APC gene oral squamous cell carcinomas.

Loss of heterozygosity involving the apc and mcc genetic loci occurs in the majority of human esophageal cancers

Loss heterozygosity detected chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), 17p13 (TP53) microdissected apocrine carcinomas breast.

Loss of heterozygosity is induced in Candida albicans by ultraviolet irradiation

Loss heterozygosity similar p53 mutations smoking lung cancer.

Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions

Loss heterozygosity mapping Wilms tumor involvement distinct regions limited function nondisjunction mitotic recombination.

Loss heterozygosity occurs D11S209 locus chromosome 11q23 invasive cervical carcinoma.

Loss heterozygosity occurs centromeric RB abnormalities retinoblastoma gene tumors patients metastatic renal cell carcinoma.

Loss of heterozygosity occurs predominantly, but not exclusively, in the epithelial compartment of pleomorphic adenoma

Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain

Loss heterozygosity 14q32 colorectal carcinoma.

Loss heterozygosity 1p uveal melanomas monosomy 3.

Loss heterozygosity 3p markers neuroblastoma tumours implicate tumour-suppressor locus distal FHIT gene.

Loss heterozygosity APC CDH1 genes laryngeal squamous cell carcinoma.

Loss of heterozygosity of APC and DCC tumor suppressor genes in human sporadic colon cancer

Loss heterozygosity APC MCC genes oral squamous cell carcinomas Taiwan.

Loss heterozygosity APC/MCC gene differentiated undifferentiated gastric carcinomas Taiwan.

Loss heterozygosity BRCA1, BRCA2 ATM genes sporadic invasive ductal breast carcinoma.

Loss heterozygosity DNA repair gene, hOGG1, renal cell carcinoma renal papillary adenoma.

Loss of heterozygosity of DPC4 tumor suppressor gene in human sporadic colon cancer

Loss heterozygosity MCC mutation retained allele sporadic colorectal cancer.

Loss heterozygosity NF1 gene juvenile chronic myelogenous leukemia neurofibromatosis type 1.

Loss heterozygosity PTEN pregnancy-associated breast cancer.

Loss heterozygosity TP53 correlated clinicopathological variables sporadic colorectal carcinomas.

Loss heterozygosity WT1 gene prognosis sporadic Wilms tumour children.

Loss heterozygosity locus chromosomal area 17p13.3 increased cell proliferation astrocytic tumors.

Loss heterozygosity locus 17p13.3, independent p53, higher grades astrocytic tumours.

Loss heterozygosity adenomatous polyposis coli gene cutaneous tumors determined polymerase chain response paraffin section preparations.

Loss heterozygosity chromosome 10p human gliomas.

Loss heterozygosity chromosome 12p correlate KRAS mutation non-small cell lung cancer.

Loss heterozygosity chromosome 13 Merkel cell carcinoma.

Loss heterozygosity chromosome 14q low- high-grade meningiomas.

Loss heterozygosity chromosome 16q gallbladder carcinoma.

Loss heterozygosity chromosome 17 human borderline invasive epithelial ovarian tumors.

Loss of heterozygosity of chromosome 1q in gastrinomas: Occurrence and prognostic significance

Loss heterozygosity chromosome 20 sporadic colorectal cancer.

Loss heterozygosity chromosome 22 dna sequences human meningioma.

Loss heterozygosity chromosome 3p sequences infrequent event endometrial cancer.

Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung

Loss heterozygosity chromosome 8 microsatellite loci implicates candidate tumor suppressor gene loci D8S87 D8S133 human prostate cancer.

Loss heterozygosity chromosome 8p 11p dysplastic nodule hepatocellular carcinoma.

Loss heterozygosity chromosome 9p loss p16INK4A expression malignant gastrointestinal stromal tumors.

Loss heterozygosity chromosome 9p, 9q expression p16 oral squamous cell carcinoma.

Loss heterozygosity chromosome 9p21 7q31 correlated high occurrence recurrent tumor head neck squamous cell carcinoma.

Loss heterozygosity chromosome 9p21 immortal phenotype neoplastic human head neck keratinocytes.

Loss heterozygosity dq alpha gene human malignant melanoma.

Loss heterozygosity gene THW frequently melanoma metastases.

Loss heterozygosity imprinted genes SV40 t/T antigen-induced hepatocellular carcinomas.

Loss heterozygosity markers chromosome 11 tumors patients multiple endocrine neoplasia syndrome type 1.

Loss heterozygosity methylenetetrahydrofolate reductase colon carcinomas.

Loss heterozygosity multiple tumor suppressor genes human gastric cancers polymerase chain response.

Loss heterozygosity nucleotide excision repair factors sporadic oral squamous cell carcinoma microdissected tissue.

Loss heterozygosity nucleotide excision repair factors sporadic ovarian, colon lung carcinomas - Implication roles carcinogenesis human solid tumors.

Loss heterozygosity p16 correlates minimal residual disease induction therapy non-high risk childhood B-cell precursor acute lymphoblastic leukemia.

Loss heterozygosity p53 gene p53 protein expression human colorectal carcinomas.

Loss heterozygosity p53 gene similar human papillomavirus cervical cancer.

Loss heterozygosity p53 oral cancers demonstrated polymerase chain response.

Loss of heterozygosity of the APC gene in oral squamous cell carcinoma

Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil

Loss heterozygosity MEN1 gene big series TSH-secreting pituitary adenomas.

Loss heterozygosity NOS3 dinucleotide repeat marker atherosclerotic plaques human carotid arteries.

Loss heterozygosity RB gene poor prognostic factor patients osteosarcoma.

Loss heterozygosity TP53 tumor suppressor gene detection point mutations non-isotopic RNAse cleavage assay prostate cancer.

Loss heterozygosity VHL gene identifies malignancy predicts death follicular thyroid tumors.

Loss heterozygosity Wilms tumor suppressor gene (WT1) in situ invasive breast carcinoma.

Loss heterozygosity human cytosolic glutathione peroxidase I gene lung cancer.

Loss of heterozygosity of the l myc oncogene in human breast tumors

Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer

Loss of heterozygosity of the nm23-H1 gene in human renal cell carcinomas

Loss heterozygosity oestrogen receptor gene breast cancer.

Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors

Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer

Loss of heterozygosity of the retinoblastoma (RB1) gene in lipomas from a retinoblastoma patient

Loss heterozygosity retinoblastoma adenomatous polyposis vulnerability gene loci chromosomes 10p, 10q 16q human prostate cancer.

Loss heterozygosity retinoblastoma p53 genes primary cervical carcinomas human papillomavirus infection.

Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma

Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial cancer

Loss heterozygosity short arm chromosomes 3 9 oral cancer.

Loss heterozygosity von Hippel Lindau gene locus polypoid dysplasia flat dysplasia ulcerative colitis sporadic adenomas.

Loss heterozygosity tumor suppressor gene loci human colorectal carcinoma.

Loss heterozygosity tumor suppressor genes testis cancer.

Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN

Loss heterozygosity 10q mutational status PTEN BMPR1A colorectal primary tumours metastases.

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: Possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary

Loss heterozygosity 17p human breast carcinomas defining smallest usual area deletion.

Loss heterozygosity 3p renal cell carcinoma von hippel lindau syndrome.

Loss heterozygosity 6q 16q 17p human nervous scheme primitive neuroectodermal tumors.

Loss heterozygosity 7q31 occurs early breast tumorigenesis.

Loss heterozygosity 8p prostate cancer implicates function dematin tumor progression.

Loss heterozygosity chromosomal segments 3p 6q 11p human ovarian carcinomas.

Loss heterozygosity chromosome 1 11 sporadic pheochromocytomas.

Loss heterozygosity chromosome 1 human hepatoblastoma.

Loss heterozygosity chromosome 10 human glioblastoma multiforme.

Loss heterozygosity chromosome 10 extensive primary (de novo) secondary glioblastomas.

Loss heterozygosity chromosome 10, 13q(Rb), 17p, p53 gene mutations human brain gliomas.

Loss heterozygosity chromosome 10p14-p15 colorectal carcinoma.

Loss heterozygosity chromosome 10q malignancy prognosis astrocytic tumors, discovery loss regions.

Loss heterozygosity chromosome 10q earlier onset sporadic colorectal adenocarcinoma.

Loss heterozygosity chromosome 10q23 mutation phosphatase tensin homolog deleted chromosome 10 tumor suppressor gene Korean hepatocellular carcinoma patients.

Loss of heterozygosity on chromosome 11 in sporadic gastrinomas

Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma

Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast

Loss heterozygosity chromosome 11p15.5 gastric carcinoma China.

Loss of heterozygosity on chromosome 11q in breast cancer

Loss heterozygosity chromosome 11q13 lobular lesions breast tissue microdissection polymerase chain response.

Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene

Loss heterozygosity chromosome 11q22-23 melanoma retention insertion polymorphism matrix metalloproteinase-1 promoter.

Loss heterozygosity chromosome 12p12-13 area Chinese patients colon carcinoma bb.

Loss heterozygosity chromosome 13 association delayed growth retinoblastoma.

Loss heterozygosity chromosome 13 squamous cell carcinoma larynx.

Loss heterozygosity chromosome 13 advanced stage prostate cancer.

Loss heterozygosity chromosome 13 usual biologically Aggressive Subtypes Ovarian Epithelial Tumors Is Associated Normal Retinoblastoma Gene Expression.

Loss heterozygosity chromosome 13q12-q14, BRCA-2 mutations lack BRCA-2 promoter hypermethylation sporadic epithelial ovarian tumors.

Loss of heterozygosity on chromosome 13q: Suggestion of a candidate tumor suppressor gene in sporadic breast cancer

Loss heterozygosity chromosome 14 nasopharyngeal carcinoma.

Loss heterozygosity chromosome 14 primary nasopharyngeal carcinoma.

Loss heterozygosity chromosome 16 hepatocellular carcinoma.

Loss heterozygosity chromosome 16p 18q anaplastic thyroid carcinoma.

Loss heterozygosity chromosome 16p13.3 hamartomas tuberous sclerosis patients.

Loss heterozygosity chromosome 16q, expression HER2/neu p53 mutations endometrial cancer.

Loss heterozygosity chromosome 17 mutation p53 gene retinoblastoma.

Loss heterozygosity chromosome 17p mutant p53 hpv negative cervical carcinomas.

Loss heterozygosity chromosome 17p predicts neoplastic progression Barrett's esophagus.

Loss heterozygosity chromosome 17p13 (p53) 13q14 (Rb1) squamous cell carcinoma head neck.

Loss heterozygosity chromosome 17p13 breast carcinomas identifies tumors high proliferation index.

Loss heterozygosity chromosome 17p13.3 ovarian cancer cervical cancer.

Loss heterozygosity chromosome 17q epithelial ovarian tumors - Association carcinomas serous differentiation.

Loss heterozygosity chromosome 17q11-21 cancers women breast ovarian cancer.

Loss heterozygosity chromosome 18q muscle-invasive transitional cell carcinoma bladder.

Loss heterozygosity chromosome 19 secondary glioblastomas.

Loss heterozygosity chromosome 1p thyroid adenoma medullary carcinoma papillary carcinoma.

Loss of heterozygosity on chromosome 1q in human breast cancer

Loss of heterozygosity on chromosome 22 in human ependymomas

Loss heterozygosity chromosome 22 human gliomas inactivate neurofibromatosis type 2 gene.

Loss heterozygosity chromosome 22 ovarian carcinoma distal accompanied mutations NF2 22q12.

Loss heterozygosity chromosome 22 sporadic schwannoma relationship proliferation tumor cells.

Loss heterozygosity chromosome 22q gastrointestinal stromal tumors (GISTs). study 50 cases.

Loss heterozygosity chromosome 2q - Possibly poor prognostic factor head neck cancer.

Loss heterozygosity chromosome 3p14.2 oral squamous cell carcinoma.

Loss heterozygosity chromosome 5 adults acute lymphoblastic leukemia.

Loss heterozygosity chromosome 5 sporadic ovarian carcinoma late event mutations APC 5q21-22.

Loss heterozygosity chromosome 5 vicinity telomere gamma-radiation-induced thymic lymphomas mice.

Loss heterozygosity chromosome 5p13-12 predicts adverse prognosis advanced bladder cancer independent tumor stage grade.

Loss heterozygosity chromosome 5q ovarian cancer frequently accompanied TP53 mutation identifies tumour suppressor gene locus 5q13.1-21.

Loss heterozygosity chromosome 6 HPV-16 positive cervical carcinomas carrying DRBI*1501-DQB1*0602 haplotype.

Loss heterozygosity chromosome 6 dichloroacetic acid trichloroacetic acid-induced liver tumors female B6C3F1 mice.

Loss heterozygosity chromosome 6q correlates decreased thrombospondin-2 expression human salivary gland carcinomas.

Loss heterozygosity chromosome 6q14-q24 poor outcome children adolescents T-cell lymphoblastic lymphoma.

Loss heterozygosity chromosome 6q27 p53 mutations epithelial ovarian cancer.

Loss heterozygosity chromosome 7q aggressive primary breast cancer.

Loss heterozygosity chromosome 7q in vitro-immortalized human oral keratinocyte cell lines.

Loss heterozygosity chromosome 8 squamous cell carcinomas head neck.

Loss heterozygosity chromosome 9 loss chromosome 9 copy number separate events pathogenesis transitional cell carcinoma bladder.

Loss heterozygosity chromosome 9 p16 (MTS1, CDKN2) gene mutations esophageal cancers.

Loss heterozygosity chromosome 9 human breast cancer - Association medical variables genetic chromosome regions.

Loss heterozygosity chromosome 9p21, 9q22.2-22.3 basal cell carcinoma, squamous cell carcinoma Bowen's disease.

Loss heterozygosity chromosome 9q p53 alterations human bladder cancer.

Loss heterozygosity chromosome 9q21 (p16 gene) unusual soft-tissue sarcomas.

Loss heterozygosity chromosome 9q22.3 microdissected basal cell carcinomas semipalatinsk nuclear testing site, Kazakhstan.

Loss heterozygosity chromosome arm 11q lung carcinoids.

Loss heterozygosity chromosome arm 16q breast cancer metastases.

Loss heterozygosity chromosome arm 17p cell lung carcinomas, neurofibromas, patient von Recklinghausen neurofibromatosis.

Loss heterozygosity chromosome arm 3p nasopharyngeal carcinoma.

Loss heterozygosity chromosome arms 3p 6q microdissected adenocarcinomas uterine cervix adenocarcinoma situ.

Loss heterozygosity chromosome arms 5q, 11p, 11q, 13q, 16p human testicular germ cell tumors.

Loss heterozygosity chromosomes 1 11 carcinoma pancreas.

Loss heterozygosity chromosomes 1 11 sporadic pheochromocytomas.

Loss heterozygosity chromosomes 1, 2, 8, 9 17 cerebral atherosclerotic plaques.

Loss heterozygosity chromosomes 1,11,12, 14 hybrid mouse lung adenocarcinomas.

Loss heterozygosity chromosomes 10 17 clinically localized prostate carcinoma.

Loss heterozygosity chromosomes 10q, 9p, 7p 13q Malays malignant glioma.

Loss heterozygosity chromosomes 11 17 markers recurrence TCC bladder.

Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma two additional regions identified

Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified

Loss heterozygosity chromosomes 1p 11p sporadic pheochromocytoma.

Loss heterozygosity chromosomes 2p, 3p, 18q21.3 11p15.5 poor prognostic factor stage II III (FIGO) cervical cancer treated radiotherapy.

Loss of heterozygosity on chromosomes 3 13 and 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung

Loss heterozygosity chromosomes 3, 9, 13, 17, including retinoblastoma locus, uveal melanoma.

Loss heterozygosity chromosomes 3p, 8p, 9p 17p progression squamous cell carcinoma larynx.

Loss heterozygosity chromosomes 7p, 7q, 9p 11q early event ovarian tumorigenesis.

Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung

Loss heterozygosity murine chromosome 6 two-stage carcinogenesis - Proof conserved tumor suppressor gene.

Loss heterozygosity X chromosome human breast cancer.

Loss heterozygosity X chromosome independent prognostic factor ovarian carcinoma: From Danish MALOVA ovarian carcinoma study.

Loss heterozygosity long arm chromosome 11 colorectal tumours.

Loss heterozygosity long arm chromosome 11 nasopharyngeal carcinoma.

Loss heterozygosity long arm chromosome 22 pheochromocytoma.

Loss heterozygosity long arm human chromosome 7 sporadic renal cell carcinomas.

Loss heterozygosity short arm chromosome 17 human astrocytomas.

Loss heterozygosity short arm chromosome 17 uterine cervical carcinomas.

Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer

Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and dna aneuploidy in primary human breast cancer

Loss heterozygosity short arm chromosome 3 carcinoma uterine cervix.

Loss heterozygosity short arm chromosome 3 cervical intra-epithelial neoplasia concomitant cervical carcinoma.

Loss heterozygosity short arm chromosome 3 mesothelioma cell lines solid tumors.

Loss heterozygosity short arm chromosome 3 nasopharyngeal carcinoma.

Loss heterozygosity short arm chromosome 3 renal cancer.

Loss heterozygosity short arm chromosome 3 sporadic, von Hippel-Lindau disease-associated, familial pheochromocytoma.

Loss heterozygosity short arm chromosome 8 male breast carcinomas.

Loss heterozygosity short arm chromosome 9 p16 gene mutation gastric carcinomas.

Loss heterozygosity short arm chromosomes 1 3 sporadic pheochromocytoma extra-adrenal paraganglioma.

Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas

Loss of heterozygosity or intragenic mutation, which comes first?

Loss of heterozygosity or: How I Learned to stop worrying and love mitotic recombination

Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination

Loss heterozygosity patterns sclerosing Hemangioma lung bronchioloalveolar carcinoma 5 related molecular pathogenesis.

Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer

Loss heterozygosity reveals non-VHL allelic loss hemangioblastomas 22q13.

Loss heterozygosity investigations deletion mapping identify putative chromosome 149 tumor suppressor loci renal oncocytomas.

Loss heterozygosity investigations retinoblastoma breast cancer vulnerability (BRCA2) loci pituitary, parathyroid, pancreatic carcinoid tumours.

Loss heterozygosity investigations squamous cell carcinomas head neck.

Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome

Loss heterozygosity investigations chromosome arm 1p harbors tumor suppressor gene renal oncocytomas.

Loss heterozygosity investigations chromosome 12q disseminated superficial actinic porokeratosis - Lessons learned.

Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas

Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma

Loss of heterozygosity testing using real-time PCR analysis of single nucleotide polymorphisms

Loss heterozygosity frequent non-exclusive mechanism responsible HLA dysregulation non-Hodgkin's lymphomas.

Loss heterozygosity, allele silencing decreased expression p73 gene breast cancers - Prevalence alterations inflammatory breast cancers.

Loss of heterozygosity, by mitotic gene conversion and crossing over, causes strain-specific adenine mutants in constitutive diploid Candida albicans

Loss heterozygosity, differentiation, clonality microdissected male germ cell tumours.

Loss heterozygosity, microsatellite instability TP53 gene status ovarian carcinomas.

Loss heterozygosity, microsatellite instability, mismatch repair protein alterations radial growth phase cutaneous malignant melanomas.

Loss heterozygosity. potential tool manipulation oral premalignant lesions?

Loss heterozygosity - The frequent recessive phenotype expression heterozygous human adenine phosphoribosyltransferase locus.

Loss hexachlorocyclohexane surface soil layers subtropical conditions.

Loss hextuple resistance amino glycoside antibiotics mycobacterium tuberculosis strain 37rv mutation isoniazid resistance incubation high temperature.

Loss hfr dna escherichia coli mero zygotes inhibition conjugation nalidixic acid.

Loss high affinity agonist binding m1 muscarinic receptors alzheimer's disease implications failure cholinergic replacement therapies.

Loss high affinity alpha 2 adrenoceptors alzheimer's disease autoradiographic study frontal cortex hippocampus.

Loss high affinity neurotensin receptors substantia nigra parkinsonian subjects.

Loss high affinity prostacyclin binding sites patients graves disease.

Loss high affinity transforming growth factor-b1 (TGF-b1) binding nephritogenic T cell results absence growth inhibition TGF-b1 augmented nephritogenicity.

Loss high affinity transforming growth factor-beta-1 (TGF-beta-1) binding nephritogenic T cell results absence growth inhibition TGF-beta-1 augmented nephritogenicity.

Loss high density lipoprotein cholesterol serum - Influence storage.

Loss high energy phosphate hyper thermia demonstrated vivo phosphorus 31 nmr spectroscopy.

Loss high flows seepage stream channels Kansas.

Loss high-affinity nicotinic receptors increases susceptibility excitotoxic lesion decreases positive effects enriched environment.

Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury

Loss high-affinity thrombin receptors platelet concentrate storage impairs reactivity platelets thrombin.

Loss high-frequency brain electrical answer thiopental administration Alzheimer's-type dementia.

Loss high-level perceptual knowledge object formation DAT.

Loss high-molecular-weight cytokeratin antigenicity prostate tissue attained transurethral resections.

Loss high-molecular-weight proteins liver microsomes rats treated hepatocarcinogens.

Loss high-responder inhibitors patients severe hemophilia A human immunoinsufficiency virus type 1 infection. report multi-center hemophilia cohort study.

Loss of highly branched arabinans and debranching of rhamnogalacturonan I accompany loss of firm texture and cell separation during prolonged storage of apple

Loss highly volatile elements ordinary chondrites impact heating.

Loss hilar mossy cells Ammon's horn sclerosis.

Loss of hilar somatostatin neurons following tetanus toxin-induced seizures

Loss hill activity extracted chloroplasts similar free fatty acid release ageing.

Loss hill activity extracted chloroplasts similar free fatty acid release aging.

Loss hill prairie woody plant invasion Pere Marquette State Park, Jersey County, Illinois.

Loss hill prairie woody plant invasion pere marquette condition park jersey province illinois usa.

Loss hippocampal CA1 neurons learning impairment subicular lesioned rats.

Loss hippocampal CA1 pyramidal neurons correlates memory impairment rats ischemic neurotoxin lesions.

Loss of hippocampal CA3 pyramidal neurons in mice lacking STAM1

Loss hippocampal acetylcholinesterase staining fornix lesion monkey.

Loss hippocampal ca1 pyramidal neurons correlates memory impairment rats ischemic neurotoxin lesions.

Loss of hippocampal neuronal nitric oxide synthase contributes to the stress-related deficit in learning and memory

Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity

Loss hippocampal theta rhythm results spatial memory deficit rat.

Loss hippocampal tritiated tcp binding alzheimer's disease.

Loss histidine decarboxylase marker malignant transformation dedifferentiation B-cells infiltrating skin - case report therapy-resistant multiple myeloma complicated skin infiltration.

Loss of histochemically demonstrable catecholamines and acetyl cholin esterase from sympathetic nerve fibers of the pineal body of the rat after chemical sympathectomy with 6 hydroxy dopamine

Loss histochemically demonstrable catecholamines glomus cells carotid body alpha methyl tyrosine cure.

Loss of histochernical identity in mast cells lacking carboxypeptidase A

Loss historical immigration unsuccessful rehabilitation extirpated salmon populations.

Loss of hla a b c allele products and lymphocyte function associated antigen 3 in colorectal neoplasia

Loss hla de novo expression hla colorectal cancer.

Loss hla locus specificities stored lymphocytes de novo synthesis incubation 37 celsius.

Loss hla class alleles heavy chains beta 2 microglobulin colorectal cancer.

Loss hla dr expression human epidermal cells growth culture.

Loss hla heavy chain beta 2 microglobulin hla negative tumors.

Loss of hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation

Loss of holocytochrome c-type synthetase causes the male lethality of X-linked dominant microphthalmia with linear skin defects (MLS) syndrome

Loss homotypic cell adhesion epithelial-mesenchymal transition mutation limits sensitivity epidermal growth factor receptor inhibition.

Loss homotypic epithelial cell adhesion selective N-cadherin displacement bismuth nephrotoxicity.

Loss host axons nerve allo grafts abolishing immunological tolerance rats.

Loss host plant specificity Manduca sexta rearing artificial diet.

Loss hostplant specificity Manduca sexta rearing artificial diet.

Loss housekeeping selenoprotein expression mouse liver modulates lipoprotein metabolism.

Loss hpv 16 e7 dependence cells transformed hpv 16 e7 ej ras correlates increased myc expression.

Loss of hsp70 in drosophila is pleiotropic, with effects on thermotolerance, recovery from heat shock and neurodegeneration

Loss human CR1- murine Crry-like exons human CR2 transcripts due CR2 gene mutations.

Loss human E-cadherin (ECD) correlated invasiveness transitional cell cancer renal pelvis, ureter urinary bladder.

Loss human corneal langerhans cells temperature cure.

Loss human cr1 murine crry exons human cr2 transcripts due cr2 gene mutations.

Loss human hippocampal adenosine A1 receptors dementia - Proof lack specificity.

Loss human immunoinsufficiency virus type 1 (HIV-1) antibodies proof viral infection asymptomatic homosexual men. report Multicenter AIDS Cohort Investigation.

Loss human immunoinsufficiency virus type 1 hiv 1 antibodies proof viral infection asymptomatic homosexual men report multicenter aids cohort study.

Loss human leucocyte antigen class I gain class II expression early events carcinogenesis - clues study Barrett's oesophagus.

Loss human leukocyte antigen expression colorectal tumor cell lines - Implications anti-tumor immunity immunotherapy.

Loss of human serum apo lipo protein c and apo lipo protein e during manipulation of diluted solutions

Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators

Loss huntingtin-mediated BDNF gene transcription Huntington's disease.

Loss husk, quality fibre coir due infestation coconut eriophyid mite (Aceria guerreronis Keifer).

Loss hyaluronate-dependent coat myoblast fusion.

Loss hybrid lethality backcross programs involving Chlamydomonas eugametos Chlamydomonas moewusii (Chlorophyceae).

Loss hybrid lethality backcross programs involving chlamydomonas eugametos chlamydomonas moewusii chlorophyceae.

Loss hybrid vigour wheat (Triticum aestivum L. em Thell) diverse densities.

Loss hybridizable ribosomal dna human post mitotic tissues aging age dependent loss human myo cardium.

Loss hybridizable ribosomal dna human post mitotic tissues aging age dependent loss human cerebral cortex hippocampal somato sensory cortex comparison.

Loss hydraulic conductivity due water stress intact juveniles Quercus rubra Populus deltoides.

Loss hydraulic conductivity due water stress intact juveniles quercus rubra populus deltoides.

Loss hydrazine stimulated mutability wild type excision repair defective yeast post cure inhibition cell division.

Loss hydrogen carbon 5 D-glucose conversion D-5-3H, 6-14C carbon isotope glucose L-ascorbic acid Pelargonium crispum (L.) LHer.

Loss of hydrogen from carbon 5 of D-glucose during conversion of D-glucose to L-ascorbic acid in Pelargonium crispum (L.) L'Her1

Loss of hydrogen from carbon 5 of d glucose during conversion of d 5 tritium labeled 6 carbon 14 labeled glucose to l ascorbic acid in pelargonium crispum cultivar prince rupert

Loss of hydrogen from di hydroxy acetone phosphate during glyceryl ether synthesis

Loss hygroscopicity due heating cellulose cellulosic materials.

Loss hymenolepis diminuta rat.

Loss of hyperpolarization-activated Cl- current in salivary acinar cells from Clcn2 knockout mice

Loss hypoglycemia awareness adolescent type 1 diabetes mellitus cure fluoxetine hydrochloride.

Loss hypothalamic dopaminergic control prolactin secretion hyper prolactinemic rat.

Loss hypothalamic nuclear bound progestin receptors factors involved relation heat termination female guinea pigs.

Loss hypoxic pulmonary vasoconstriction (HPV) mice lacking malonyl CO-A decarroxylase.

Loss hypoxic pulmonary vasoconstriction chronic pneumonia mediated nitric oxide.

Loss hypoxic ventilatory answer bilateral neck dissection.

Loss ia bearing splenic adherent cells body uv irradiation.

Loss of ia positive epidermal langerhans cells at the onset of type 1 insulin dependent diabetes mellitus

Loss ice accreting giant-icy-satellites escape hot proto-atmospheres.

Loss ice container openings liquid-ice cooling horticultural crops.

Loss ice-nucleating activity avoidance inoculative freezing puparium structure stimulated 20-hydroxyecdysone Eurosta solidaginis (Diptera - Tephritidae).

Loss ichthyoplankton due wild harvest shrimp seeds Indian sundarbans.

Loss of identity: New Zealand soccer, its foundations and its legacies

Loss ileal IgA+ plasma cells CD4+ lymphocytes ileal Peyer's patches vitamin A deficient rats.

Loss image quality photobleaching microscopic imaging fluorescent probes bound chromatin:.

Loss immune components processing human milk.

Loss immunity pertussis rural community Senegal.

Loss immuno reactive arginine vasopressin electrical stimulation silver electrodes.

Loss immunogenecity liver dendritic cells mouse chronic hepatitis.

Loss immunogenic properties vaccinia virus inactivated formaldehyde.

Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations

Loss immunological biological activity insulin human muscle extract.

Loss of immunoreactivity for RTI40, a type I cell-specific protein in the alveolar epithelium of rat lungs with bleomycin-induced fibrosis

Loss immunoreactivity human calmodulin-like protein early event breast cancer progress.

Loss immunostaining RBP-J-vkappa transcription factor F9 cell differentiation stimulated retinoic acid.

Loss imprinted genes paternal SUR1 mutations lead focal form congenital hyperinsulinism.

Loss imprinted genes paternal SUR1 mutations lead hyperinsulinism focal adenomatous hyperplasia.

Loss imprinting allele switching p73 renal cell carcinoma.

Loss imprinting cancer.

Loss imprinting loss heterozygosity 11p15.5 head neck squamous cell carcinomas.

Loss imprinting overexpression IGF2 gene gastric adenocarcinoma.

Loss imprinting promoter utilization IGF2 laryngeal squamous cell carcinoma.